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Abstract: Calcium phosphate nanoparticles (nanoCaP) conjugated with cis-diamminedichloro-
platinum (CDDP, cisplatin) were prepared through the electrostatic binding of an aquated species 
of cisplatin to the nanoCaP in a chloride-free solution. The agglomeration of the nanoCaP that 
typically occurs during synthesis of CaP was controlled through the addition of DARVAN® 
811 immediately after precipitation and before drug conjugation. In vitro drug release studies 
were completed and showed a sustained release of CDDP from the nanoconjugates over time. 
The cytotoxicity of the nanoCaP/CDDP was compared to that of the free drug in an in vitro 
cell proliferation assay using the CDDP resistant A2780cis human ovarian cancer cell line. 
The CDDP released from the nanoconjugates was equally effective as the free drug against the 
A2780cis cell line. Direct addition cytotoxicity studies revealed that the sterically-stabilized, 
negatively-charged drug nanoconjugates are unable to overcome drug resistance and had an 
increased IC50 value as compared to the free drug.
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Introduction
Attachment of a pharmaceutical to a particulate drug delivery system is a tactic that has 
long been employed to sustain drug delivery. Particulate drug carrier systems for tumor 
speciﬁ  c targeting of anti-cancer drugs include liposomes (Gregoriadis 1995; Allen and 
Moase 1996; Vicent and Duncan 2006), polymer microspheres (Fung and Saltzman 
1997; Liu et al 2003; Lin et al 2005; Foger et al 2006) and recently nanoparticles (Barbe 
et al 2004; Ambruosi et al 2006; Dong and Feng 2006; Farokhzad et al 2006). Although 
liposomal systems have made the most headway in the clinic, they are under further 
optimization to be safer to normal tissues and long-circulating in blood, yet able to 
efﬁ  ciently accumulate and transfer drug in a sustained manner to targeted sites (Hong 
et al 1999). For biodegradable polymer-based drug delivery systems, there are concerns 
that polymer acidic byproducts or degrading polymer fragments can adversely affect the 
drug they are delivering or the tissues they interact with. Often an undesirable late stage, 
uncontrolled and massive drug release is observed with polymer-based drug delivery 
systems (Spenlehauer et al 1989). Bioceramics, such as calcium phosphates (CaP), 
represent another class of materials suitable for use as a carrier for drugs, non-viral 
gene delivery, antigens, enzymes, and proteins. CaP can be produced at a low cost and 
is simple to manufacture. Hydroxyapatite (HA) is a type of calcium phosphate that has 
a similar chemical structure to bone mineral, and hence has excellent biocompatibility, 
bioactivity, and high afﬁ  nity to proteins (Gorbunoff 1984a, 1984b; Spenlehauer et al 
1989), DNA (Welzel et al 2004; Bisht et al 2005), chemotherapy drugs (Barroug et al 
2004), and antigens (He et al 2000).
Localized pharmaceutical treatments utilizing CaP as a drug carrier have been 
achieved by injections (He et al 2000) or surgical placement of disks, pellets or par-
ticulates (Yamamura et al 1994; Itokazu et al 1998; Rogers-Foy et al 1999; Benghuzzi International Journal of Nanomedicine 2007:2(4) 668
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2000; Mizushima et al 2006). The localized drug release from 
these CaP-based controlled release systems minimized the 
high concentration of drugs typically required in the blood-
stream and other organs to achieve therapeutic outcomes. 
The CaP also provided a means to minimize unnecessary 
systemic toxicity and reduce the need for repeated dosing 
often required of most drugs. Due to the low solubility of 
the HA type of CaP in physiological conditions, HA remains 
for long periods after in vivo subcutaneous placement. The 
large sintered disks and large particle sizes of HA utilized in 
the previously researched formulations would remain in vivo 
long after drug release. This led to our interest in investigat-
ing nano-sized CaP particles that could speed carrier resorp-
tion, allow greater tumor or tissue perfusion, and perhaps 
overcome drug resistance through intracellular drug/particle 
uptake observed with particulate drug delivery formulations 
(Minko et al 1998). Particle enhanced endocytosis may 
endow the particulate drug delivery systems with an ability 
to bypass p-glycoprotein efﬂ  ux pump and lead to sequestra-
tion of anticancer drugs in acidic intracellular compartments, 
yielding high cytotoxicity (Lee et al 2005).
In order to use nanoCaP crystals as an efﬁ  cient drug 
carrier for localized chemotherapy treatment, it is important 
that the chemotherapy drug can be loaded and released in 
a controlled manner. Moreover, it is also important that the 
drug released is chemically active and effective over a long 
period of time. Therefore we investigated these variables 
using Cisplatin (CDDP), a commonly used chemotherapy 
drug with high antitumor activity (Long and Repta 1981; 
Barroug et al 2004) as the model drug. Our approach can 
be generalized to other drugs and biomolecules due to the 
versatility of the CaP crystal surface to bind both positively 
and negatively charged molecules through simple adsorp-
tion. In the present study, we describe the preparation of 
nanoCaP/CDDP conjugates with controlled size and purity. 
The in vitro drug release proﬁ  le of the nanoconjugates is 
investigated. The cytotoxicity of the released drug and 
directly added nanoCaP/CDDP is compared to that of the free 
drug in an in vitro cell proliferation assay using the CDDP 
resistant A2780cis human ovarian cancer cell line.
Experimental procedures
Nano-calcium phosphate particle 
synthesis
NanoCaP was synthesized by co-precipitation from the 
addition of equal volumes of a 30 mM Ca(NO3)2 solution 
and a 30 mM K2HPO4 solution which are both ﬁ  ltered 
through 0.1 μm ﬁ  ltration device (Millipore, Boston, USA) 
separately, followed by immediate addition of 1.67(v/v)% of 
0.2 μm ﬁ  ltered DARVAN®811 (sodium polymethacrylate, 
MW = 3,300, R.T. Vanderbilt Company, Inc. Norwalk, CT, 
USA) as a dispersing agent. All reagents are ACS grade and 
purchased from Sigma Chemical Co., (St. Louis, MO), unless 
noted otherwise. After 1 hr stirring, a pellet of nanoCaP 
was collected by centrifugation at 12,000 rpm (20,076 g) 
for 30 min. Before binding, the nanoCaP pellet was redis-
persed in ultrapure H2O as a wash step, and then collected 
by centrifugation at 12,000 rpm for 30 min.
NanoCaP/CDDP conjugate synthesis
CDDP (Sigma Chemical Co., St. Louis, MO) was bound to 
nanoCaP by following a slight modiﬁ  cation of the electrostatic 
conjugate preparation procedure we developed previously 
(Barroug and Glimcher 2002). Following the recommenda-
tion of Dr. S. Lippard, (Chemistry Dept., Massachusetts Insti-
tute of Technology, Cambridge, MA, USA), the aquated form 
of CDDP was prepared and used instead of CDDP to more 
efﬁ  ciently form the conjugates. Aquated CDDP was prepared 
by reacting 90 mM AgNO3 solution with CDDP solution 
(about 1000 μg/mL) at a 2:1 molar ratio. The reaction mixture 
was placed on a thermal rocker (Lab-Line®, model 4637) for 
12–24 hrs and kept protected from light. The silver chloride 
precipitate was removed by several centrifugation steps at 
3000 rpm (1000 g) for 20 min. The remaining supernatant 
was ﬁ  ltered through a 0.2 μm ﬁ  lter. The ﬁ  nal concentration 
of aquated CDDP was determined by Pt analysis using an 
Atomic Absorption Spectrophotometer (AAS) (Model 5100, 
Perkin Elmer, Shelton, CT, USA).
The nanoconjugates were formed by adding 0.625 mL 
of 20 mM potassium phosphate buffer (KPB, pH = 6) to 
31.55 mg of a wet nanoCaP pellet (which corresponds to 5 mg 
of dry CaP as determined by oven drying), and sonicating 
for 10 sec. Aquated CDDP (0.625 mL with initial binding 
CDDP concentration C0) was added, and the sample was 
put in a thermorocker at 37 °C, speed 5 (LAB-LINE® ther-
morocker, Model 4637, Barnstead Thermolyne, IL, USA) 
for 4 hrs. The conjugates thus formed were centrifuged at 
12,000 rpm (20,076 g) for 30 min. The supernatant, which 
contained unbound CDDP, was decanted and measured for 
ﬁ  nal binding supernatant CDDP concentration (Cf) by AAS. 
The pellet was washed with 0.25 mL 10 mM KPB buffer and 
centrifuged at 12,000 rpm(20,076 g), 30 min. The supernatant 
from this KPB wash was decanted and measured by AAS 
to determine KPB wash supernatant CDDP concentration 
(CKPB). This pellet was rinsed with 0.21 mL of 0.9% NaCl 
solution for 30 min. on the thermorocker (37 °C, speed 5) International Journal of Nanomedicine 2007:2(4) 669
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after brief sonication. The sample was centrifuged again 
at 12,000 rpm for 30 min. to collect the nanoCaP/CDDP 
conjugates. The supernatant was decanted and measured for 
saline wash supernatant CDDP concentration (Cw). The drug 
loading was calculated by the following equation:
  
where V0, VKPB, and Vw are the volume of initial aquated 
CDDP, 10 mM KPB buffer, and NaCl used, respectively. 
Drug loading efﬁ  ciency deﬁ  ned as μg adsorbed CDDP/μg 
CDDP in the starting solution was also calculated.
Three batches of nanoconjugates were synthesized asepti-
cally for the different studies. Volumes of the precipitation 
solutions were varied proportionally depending on the yield 
of conjugates required. The drug loading of the nanoconju-
gates was controlled by changing the initial aquated CDDP 
concentration (C0). The drug loading of the nanoconjugates 
used for the direct addition cytotoxicity study was 112 μg/mg 
obtained by using 1052 μg/mL aquated CDDP. The drug 
loading efﬁ  ciency was 0.85. The drug loading of nanocon-
jugates used for in-vitro drug release study was 88 μg/mg 
by using 900 μg/mL aquated CDDP and the drug loading 
efﬁ  ciency was 0.78. The drug loading of the conjugates 
used for cytotoxicity test was 35 μg/mg by using 552 μg/mL 
aquated CDDP and drug loading efﬁ  ciency was 0.5.
Physical and chemical characterization of 
nanoCaP and nanoCaP/CDDP conjugates
Samples were prepared for transmission electron microscopy 
(TEM) by dispersing nanoCaP/CDDP conjugates in ultrapure 
H2O at about 1 mg/mL concentration with an Ultrasonic 
1000L Cell Disruptor (Ultrasonic Power Corporation, IL, 
USA) for 1 minute. One drop of this liquid was immediately 
transferred by a micropipette to a 3 mm diameter Formvar 
coated copper TEM grid and slowly evaporated to dryness. 
The samples on the TEM grid were analyzed using a 100cx 
JEOL TEM at 80 kV in brightﬁ  eld (BF) modes.
The chemical structure of nanoCaP was determined by 
FTIR as follows. Infrared absorption spectra were obtained 
from nanoCaP in a KBr pellet using a Bruker Tensor 27 Fou-
rier transform infrared (FTIR) spectrometer with a resolution 
of 0.1cm–1. X-ray diffraction analysis was used to determine 
the crystal structure of nanoCaP. The samples were scanned 
with Cu-Kα x-ray radiation from a Philips XRD 2500 at 
40 KV and 20 mA, using a step size of 0.02° and a step time 
of 1.2 s over a 2θ range of 10–70. The particle size of the 
nanoCaP and nanoCaP/CDDP conjugates were measured 
on samples dispersed in ultrapure H2O at about 1 mg/mL 
concentration by Ultrasonic 1000L Cell Disruptor. The 
particle size and Z-potential of nanoparticles was measured 
on 90 Plus particle sizer coupled with Z-potential analyzer 
(Brookhaven Instruments, NY, USA).
In vitro drug release studies
Release studies were conducted by dispersing 40 mg of 
nanoCaP/CDDP conjugates (88 μg/mg loading), by mixing 
and brief vortexing, in 0.8 mL PBS and rocking at 37 °C, 
20 cycle/min. Supernatants were collected at 1hr, 6 hr, 1, 3, 
7, 12, and 16 days, after centrifugation at 9,000 rpm (7,000 g) 
for 10 minutes. The released drug in the unﬁ  ltered supernatant 
was measured by AAS. Full replacements of release media 
were made at each time point.
In vitro cytotoxicity testing
For in vitro cytotoxicity activity studies, the CDDP-resistant 
cell line was used: A2780cis human ovarian carcinoma cell 
line (Sigma, 93112517) and cultured according to supplier’s 
descriptions. Brieﬂ  y, cells were cultured in RPMI1640 
medium, supplemented with 2 mM Glutamine and 10% 
Fetal Bovine Serum (FBS) in a humid atmosphere at 37 °C 
and 5% CO2. Cells were supplemented with 1μm CDDP 
to the culture media every 2–3 passages, post-attachment. 
The CellTiter96® AQueous One (Promega Corporation, 
Madison, WI, USA) colorimetric proliferation assay was 
used to determine the IC50 value (50% inhibitory concen-
tration) evaluated from 12 two-fold dilutions of CDDP 
in 0.9% saline (free drug), nanoconjugates, nanoCaP and 
free drug, or CDDP released from the nanoconjugates. The 
highest concentrations of test samples were prepared in 
the drug master plate prior to dilution as follows: CDDP 
was dissolved in 0.9% saline at 1000 μg/mL and diluted in 
PBS to prepare a free drug solution of 200 μg CDDP/mL. 
CDDP released from the nanoconjugates was obtained 
from the supernatant of 40 mg of nanoconjugates (loaded 
at 35 μg CDDP/mg nanoCaP) incubated in 0.8 mL PBS for 
3d on a rocker at 37 °C, 20 cycles/min. Three days were 
necessary to achieve a CDDP concentration high enough to 
obtain an IC50 value. Five milligrams of nanoCaP/CDDP, 
synthesized aseptically with a drug loading of 112 μg 
CDDP/mg CaP, was dispersed in 0.8 mL PBS (CDDP 
700 μg/mL if totally released) for the highest nanoconjugate 
concentration directly added. To conﬁ  rm that the particu-
late nanoconjugates were diluted evenly across the wells, 
(1)
μ
=− − −
g adsorbed CDDP/mg of CaP
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measurements of the total Pt concentration in all the wells 
of the drug master plate were made by AAS after dissolving 
the nanoconjugate solutions in dilute HCl. Five milligrams 
of nanoCaP was dispersed in 0.8 mL free drug solution for 
the nanoCaP not conjugated to free drug sample, directly 
added to cells.
Preliminary investigations of the growth rate of A2780cis 
were conducted to determine the proper cell seeding number 
that would remain in the linear range of the assay throughout 
the study. The cytotoxicity assay was conducted as follows: 
twenty-four hours after seeding 2000 A2780cis cells in 
50 μl of media on 96 well plates, 50 μl PBS, or PBS with 
drug, carrier or nanoconjugates was added to the wells. Five 
replicates were tested for each sample. Following two days 
of continuous exposure, 20 μl of CellTiter96® AQueous One 
(Promega) colorimetric proliferation reagent was added to 
each well, and then the plates were incubated for 4 more hours 
before being read on a Spectramax Plus384 spectrophotometer 
(Molecular Biosciences, Sunnyvale, CA, USA) at an absor-
bance value of 490nm. Absorbance values were converted to 
IC50 values using the four parameter logistic equation:
   (2)
where
Y = observed absorbance
Amax = absorbance of control cells
Amin =   absorbance of cells in presence of highest agent 
concentration
x = drug concentration (μg/ml)
n = slope of curve
Samples were analyzed for statistically signiﬁ  cant dif-
ferences using the Student’s T-test (p   0.05).
Results
Physical and chemical characterization
of the nanoCaP and the nanoCaP/CDDP 
conjugates
A combination of several methods was used to fully charac-
terize the nanoconjugate shape, size, chemistry and structure. 
TEM images showed that the nanoconjugates are spherical 
and well dispersed (Figure 1a). The mean particle size of the 
nanoCaP precipitated with DARVAN 811 before conjugation 
with CDDP was 129 ± 33 nm (50% below 125.4 nm, 90% 
below 181.3 nm), and the zeta-potential = −45.59 mV. The 
size and zeta-potential slightly decreased after adsorbance of 
CDDP: 106.5 ± 35.4 nm (50% below 101.1 nm, 90% below 
163.3 nm), zeta-potential = –27.9 mV (Figure 1b). Solutions 
of nanoconjugates remain stably dispersed for periods of up 
to at least two weeks. The FTIR spectra of the nanoCaP and 
the nanoconjugates have similarities to HA (Elliott 1994; 
Zhang and Colwell 2004; Liu et al 2005), and not other 
calcium phosphate phases, except that several peaks associ-
ated with the DARVAN 811 are present in the nanoparticles 
(Figure 2). However, there is a lack of resolution of the P-O 
absorption bands, indicating that the sample may contain 
amorphous calcium phosphate (Legeros et al 2005). The 
R-COO- stretch in the DARVAN 811 is changed from 1573 
cm–1 to 1559 cm–1 which is possibly due to intermolecular 
bridge R-COO-Ca complex formation with the CaP (Zhang 
et al 2006). The X-ray diffraction spectra (Figure 3) of the 
nanoCaP contains broad peaks characteristic of HA. The 
broad peaks of the nanoCaP relative to the HA standard 
peaks indicates that the crystals are nanometer in size, poorly 
crystalline or perhaps amorphous. The sample does not show 
any evidence of contamination from other crystalline calcium 
phosphate phases.
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Figure 1 (a) TEM image of nanoCaP/CDDP conjugates. (b) Particle size analysis of nanoCaP/CDDP conjugates redispersed in H2O at 1 mg/mL concentration. NanoCaP/
CDDP particle size = 106.5 ± 35.4 nm (mean size ± standard error, 50% below 101.1 nm, 90% below 163.3 nm), Z-potential = −27.9 mV. The control NanoCaP: Particle
size = 129 ± 33 nm, 50% below 125.4 nm, 90% below 181.3 nm. Z-potential = −45.59 mV.
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Figure 2 FTIR spectrum of (a) DARVAN 811 (b) Commercial hydroxyapatite 
standard and (c) NanoCaP formed in the presence of DARVAN 811 (d) NanoCaP/
CDDP conjugates.
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Figure 3 XRD spectrum of nanoCaP particles compared to a hydroxyapatite 
standard (JCPDS, #09-0432). 
In vitro drug release from nanoCaP/
CDDP conjugates
The amount of CDDP released from the nanoconjugates into 
PBS, pH = 7.4 during gentle rocking at 37 °C at various time 
points is shown in Figure 4a. The results are also expressed as 
a percentage of the total amount bound (Figure 4b). There is 
a burst release of drug in the ﬁ  rst day, followed by a slower, 
but continuous, release of drug over the time tested. After 
16-days in PBS with eight solution changes, 30% of the 
bound drug released.
Cytotoxicity of nanoCaP/CDDP 
conjugates
The effect of the CDDP conjugated to nanoCaP on the pro-
liferation of A2780cis cancer cells was evaluated indirectly 
and directly by (a) addition of the CDDP released from the 
nanoconjugates during incubation in PBS for three days, and 
(b) direct addition of the nanoconjugates to the cells in cul-
ture. The IC50 value obtained for the nanoconjugate-released 
CDDP was not signiﬁ  cantly different from the free drug 
(p   0.05) (Figure 5), indicating the conjugation procedure 
and the release process do not adversely affect CDDP. The 
IC50 value obtained after direct addition of the nanoconju-
gates is also shown in Figure 5. Determination of the IC50 
value for directly added nanoconjugates was complicated by 
the fact that the nanoCaP and the nanconjugates themselves 
have an absorbance maximum at 490 nm, the same as the 
formazan product produced by the viable cells in the assay. 
Therefore, it was necessary to deduct the interference of the 
nanoCaP using the readings from wells prepared using the 
same conditions as above (same seeding cell number, same 
nanoconjugate or nanoCaP concentration and volume, same 
culture time) without the addition of CellTiter96® reagent, as 
shown in Figure 6. The IC50 values obtained this way indicate 
that the addition of the carrier alone (nanoCaP) to a free drug 
solution slightly, but signiﬁ  cantly, increases the IC50 value 
relative to the free drug alone. This provides indirect evidence 
that the nanoCaP itself is not cytotoxic at the concentration 
tested. The IC50 value of the nanoconjugates was found 
to be signiﬁ  cantly higher than the free drug (17.6 ± 2.7 vs 
3.2 ± 0.2) indicating that a portion of the CDDP attached to 
the nanoconjugates is protected from direct interaction with 
the cells during the two-day test period.
Discussion
In our previous experiments with CDDP release from differ-
ent types CaP, we observed that the less crystalline the CaP, 
the slower the release of drug (Barroug et al 2004). This effect 
was correlated to particle surface area: particles with higher 
surface areas bind more drug and release it more slowly 
and less completely than particles with lower surface areas. 
Therefore, varying the crystallinity is one means of control-
ling drug release in inorganic particle-based drug delivery 
systems. Given that the nanoCaP of this study appears to be 
even less crystalline than the CaP tested in our previous work, 
it is not surprising that the initial burst release and the cumula-
tive drug release from the nanoconjugates in the present study 
was even lower than that observed previously for CaP. The 
reduction of a burst release and enhanced sustained release 
possible with the nanoconjugates is desirable for in vivo 
applications. While there is low cumulative release in neutral 
PBS, the nanoconjugates are completely soluble in acidic 
solutions. This property may make the nanoCaP/CDDP drug International Journal of Nanomedicine 2007:2(4) 672
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delivery system particularly suited for in vivo intratumoral 
drug delivery applications in which the acidic pH of tumor 
tissue will lead eventually to complete drug release.
The reduced cytotoxicity of the nanoconjugates relative to 
free drug seen in the direct addition studies also conﬁ  rms that 
a large portion of CDDP attached to the CaP is not released 
over two days in neutral pH cell culture medium. From the 
in vitro release studies (Figure 4), approximately 12% of the 
total CDDP bound would be expected to be released by the 
end of the two day incubation with cells. The 12% is prob-
ably an overestimate since the release study was conducted 
with solution agitation and multiple total solution replace-
ments, while the cell culture media was not disturbed or 
replaced. Assuming 10% release, of the 350 μg/ml available 
for release from the conjugates, only 35 ug/ml of free drug 
would have been available at the highest concentration to 
the cells compared to the 100 ug/ml in the free drug wells. 
If the concentrations of the nanoconjugates were adjusted 
to this theoretical value and the IC50 values recalculated, 
the IC50 would be 1.7 μg/mL, which is less than free drug 
(3.2 μg/mL). Therefore it appears that more of the CDDP 
than expected from cell-free in vitro release studies is being 
released when in contact with cells. This would be possible 
if some endocytosis of the nanoconjugates occurred as 
has been reported for particle based drug delivery systems 
(Minko et al 1998).
Previous studies with CaP have shown that unsintered 
microcrystals of HA are readily taken up by cancer cells 
(Aoki 1994), therefore we had anticipated extensive particle-
assisted drug transport. If this had been the case, then the 
nanoconjugates would have overcome the drug resistance 
of the A2780cis cells (lower IC50 than free drug), which 
they did not. There is literature indicating that negatively 
charged particles are less likely than neutral particles to 
be taken up by cells (Bonhomme et al 1992), and since the 
nanoCaP/CDDP is negatively charged, cellular uptake may 
have been reduced because of the negative surface charge. 
Endocytotic uptake can be categorized into nonspeciﬁ  c 
ﬂ  uid phase endocytosis, adsorptive endocytosis and speciﬁ  c 
receptor-mediated endocytosis (Yi et al 2005). Adsorptive 
endocytosis requires nanoparticle adsorption on the cell 
membrane to obtain cytotoxicity and has been observed for 
doxorubicin-loaded polyalkylcyanoacrylate nanoparticles 
(Vauthier et al 2003). CaP crystals with unmodiﬁ  ed surfaces 
have been shown to adsorb to cells in culture (Mandel and 
Riese 1991), therefore particle uptake of our nanoCaP was 
expected. However, in the present study we modiﬁ  ed the 
surface of the nanoCaP with DARVAN 811 to prevent the 
adhesion of nanoparticles to each other through steric stabi-
lization. This modiﬁ  cation appears to have also prevented 
or greatly reduced cell membrane adhesion required for CaP 
particle-assisted drug transport. Overcoming this may require 
applying an additional surface modiﬁ  cation such as a tumor 
cell targeting ligand (eg, folic acid, VEGF) (Marcucci and 
Lefoulon 2004; Minko et al 2004).
Conclusion
Stably dispersed nanoparticles of CaP were synthesized by 
the addition of DARVAN 811 immediately after precipita-
tion. Aquated CDDP was simply and efﬁ  ciently adsorbed 
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to the surface of CaP nanoparticles through electrostatic 
interactions. The high surface area of the CaP nanoparticles 
led to a reduction of the CDDP burst release and greater 
sustained release relative to more crystalline, micron-sized 
agglomerated particles of CaP previously tested. In vitro 
cytotoxicity testing showed that the CDDP released from the 
nanoconjugates retained complete activity during conjugation 
and release and had comparable cytotoxicity to free drug. 
The nanoCaP alone was not cytotoxic. CDDP release from 
CaP nanoconjugates in neutral pH was slow and complete 
release was limited (30%), therefore the direct addition 
studies showed reduced cytotoxicity of the nanoconjugated 
CDDP relative to free drug. Particle assisted drug transport 
was not a highly active mechanism in this formulation, pos-
sibly due to the negative surface charge or steric stabilization 
by the DARVAN 811. However, we postulate that in acidic 
environments such as tumor tissues, the CaP nanoconjugates 
can slowly dissolve and completely release the adsorbed 
drug. The favorable properties of nanoCaP/CDDP conjugates 
warrant their further investigation in intratumoral anti-cancer 
drug delivery applications.
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